PDCD1 and non-small cell lung carcinoma: Besides, Park et al. (52) concluded the predictive effects of anti-PD-1/L1-associated irAEs for favorable clinical outcomes in a recent systematic review, which only covered 11 studies of NSCLC treated with anti-PD-1 regimens.